Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares China Large-Cap ETF (FXI) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares China Large-Cap ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares China Large-Cap ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while iShares China Large-Cap ETF trades at $35.35. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.

AMLXFXI
Market Cap
$2.53B
Sector
Health
52-Week High
$24.19$41.75
52-Week Low
$7.82$31.59
Enterprise Value
$2.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

iShares China Large-Cap ETF

FXI, the iShares China Large-Cap ETF, trades at $36.17, up 0.61% on the day, with a bullish technical signal driven by moving averages. The ETF benefits from China's strong export data and state-backed economic support, though key financial ratios are not disclosed in the provided data. Recent news highlights China's AI and manufacturing strength as positive catalysts.

Outlook is cautiously optimistic given bullish technicals and macroeconomic tailwinds, but risks include U.S.-China tensions and reliance on financials-heavy exposure. The dividend announcement for 2026 provides income appeal, yet investors face volatility from geopolitical and regulatory uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI